We have previously shown that genome editing of the mutant Ryr2 allele could correct the CPVT phenotype and lethal arrhythmias in a p.Arg176Gln (R176Q/+) heterozygous mouse model[12]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.